Jul. 22 at 10:13 PM
$KZIA Shareholders prefer to see Director stock options, close to the money. Only earlier this month, was this Kazia stock options announcement made. That out of the way, means now is the time for real PR. The company know full well of the potential. More than anybody, mgment realize the potential- and the stock moving to
$100, so the less said about the cheap options, the better. By choice, the trial continues in TNBC. It is called "triple negative" because the cancer cells test negative for three specific receptors that fuel most other breast cancers: estrogen receptors, progesterone receptors, and the HER2 protein.Because these tumor cells lack all three markers, hormone therapies and drugs targeting HER2 are ineffective, making the cancer more challenging to treat and often more aggressive. Celcuity excluded TNBC. Yet we are seeing profound and dramatic tumor reductions in just 3 weeks. The market gives no credit to the difficulty and confidence in meeting the TNBC challenge.
